PRESS RELEASE published on 08/30/2023 at 14:30, 2 years 8 months ago The Science Times Publishes Article About Jaguar Health's Focus on Developing Crofelemer for Two Rare Disease Indications
PRESS RELEASE published on 08/28/2023 at 14:30, 2 years 8 months ago Jaguar Health to Present September 7 at Emerging Growth Conference and at the September 11-13 H.C. Wainwright Annual Global Investment Conference
PRESS RELEASE published on 08/24/2023 at 13:00, 2 years 8 months ago Jaguar Health Engages B2i Digital to Deploy Cutting-Edge Investor Engagement Campaign
PRESS RELEASE published on 08/17/2023 at 14:30, 2 years 8 months ago Napo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea
PRESS RELEASE published on 08/16/2023 at 14:30, 2 years 8 months ago Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption
PRESS RELEASE published on 08/14/2023 at 14:00, 2 years 8 months ago Jaguar Health Reports Second Quarter 2023 Financial Results
PRESS RELEASE published on 08/10/2023 at 14:30, 2 years 8 months ago Jaguar Health to Hold Investor Webcast Monday, August 14th at 8:30 AM EDT Regarding Q2 2023 Financials & Corporate Updates
PRESS RELEASE published on 08/09/2023 at 14:30, 2 years 8 months ago Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to BARDA for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
PRESS RELEASE published on 08/08/2023 at 14:30, 2 years 8 months ago Napo Pharmaceuticals, a Jaguar Health Company, Announces Activation by FDA of Investigational New Drug (IND) Application for Crofelemer for Treatment of Microvillus Inclusion Disease
PRESS RELEASE published on 08/07/2023 at 14:30, 2 years 8 months ago Independent Study Published in Clinical Breast Cancer Shows Activity of Jaguar Health's Crofelemer for Neratinib-induced Diarrhea
Published on 05/02/2026 at 21:00, 16 hours 35 minutes ago GECC Subsidiary Provides Update on its Lawsuit for Damages Against the Lender of the Atmosphere Project
Published on 05/02/2026 at 01:30, 1 day 12 hours ago Uraniumx Reports Strong Financial Position Ahead of Spring Drill Program
Published on 05/02/2026 at 00:50, 1 day 12 hours ago CoTec Announces Annual Stock Option, Restricted Share Unit And Deferred Share Unit Grants
Published on 05/02/2026 at 00:00, 1 day 13 hours ago Redwood AI Announces Enhanced AI Models, Increasing Evaluated Chemical Reactions Following Preliminary Results from UBC Collaboration
Published on 05/02/2026 at 00:00, 1 day 13 hours ago Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
Published on 05/03/2026 at 04:45, 8 hours 50 minutes ago GWM Unveils World-Class Safety & Testing Facilities: Safety Built on Data, Not Hype
Published on 05/02/2026 at 15:35, 22 hours ago Ecuador's banana sector renews labor agreement, with jobs meeting global standards
Published on 05/01/2026 at 19:23, 1 day 18 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/30/2026 at 20:00, 2 days 17 hours ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 2 days 18 hours ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 2 days 18 hours ago Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 2 days 19 hours ago Minutes of the Combined General Meeting held on April 30, 2026
